Harbor Advisors LLC continued to hold its position in Horizon Pharma PLC (NASDAQ:HZNP) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,000 shares of the biopharmaceutical company’s stock at the close of the second quarter. Harbor Advisors LLC’s holdings in Horizon Pharma PLC were worth $178,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Profund Advisors LLC boosted its stake in Horizon Pharma PLC by 0.8% in the first quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock valued at $200,000 after acquiring an additional 112 shares during the period. US Bancorp DE boosted its stake in Horizon Pharma PLC by 1.2% in the first quarter. US Bancorp DE now owns 32,050 shares of the biopharmaceutical company’s stock valued at $473,000 after acquiring an additional 368 shares during the period. Prudential Financial Inc. boosted its stake in Horizon Pharma PLC by 2.6% in the first quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 420 shares during the period. Sheaff Brock Investment Advisors LLC boosted its stake in Horizon Pharma PLC by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 500 shares during the period. Finally, Amalgamated Bank boosted its stake in Horizon Pharma PLC by 4.8% in the second quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 943 shares during the period. Institutional investors and hedge funds own 82.33% of the company’s stock.

HZNP has been the subject of a number of research reports. ValuEngine downgraded Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub upgraded Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Cantor Fitzgerald set a $13.00 target price on Horizon Pharma PLC and gave the company a “buy” rating in a research note on Monday, July 31st. Jefferies Group LLC restated a “buy” rating and issued a $14.00 target price on shares of Horizon Pharma PLC in a research note on Friday, July 14th. Finally, Piper Jaffray Companies set a $18.00 target price on Horizon Pharma PLC and gave the company a “buy” rating in a research note on Sunday, September 10th. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Horizon Pharma PLC currently has an average rating of “Buy” and a consensus price target of $18.00.

Shares of Horizon Pharma PLC (NASDAQ HZNP) traded up 0.44% during midday trading on Thursday, reaching $13.73. The company had a trading volume of 1,125,478 shares. The firm’s 50 day moving average price is $12.93 and its 200-day moving average price is $12.75. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $21.98. The company’s market capitalization is $2.24 billion.

Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The business had revenue of $289.51 million for the quarter, compared to analysts’ expectations of $237.01 million. During the same period in the prior year, the firm earned $0.56 earnings per share. Horizon Pharma PLC’s revenue was up 12.5% compared to the same quarter last year. Analysts anticipate that Horizon Pharma PLC will post $1.07 earnings per share for the current fiscal year.

WARNING: This article was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/05/horizon-pharma-plc-hznp-stake-held-by-harbor-advisors-llc.html.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Stock Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related stocks with our FREE daily email newsletter.